Table of Content

Chapter 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in investment for the research and development of psychedelic drugs.
3.4.1.2. Increased social acceptance of psychedelic drugs.
3.4.1.3. Rise in prevalence of mental illness.
3.4.2. Restraints
3.4.2.1. Safety concerns regarding the use of psychedelic drugs
3.4.3. Opportunities
3.4.3.1. Rise in awareness about mental health
Chapter 4: PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Ketamine
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Psilocybin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
Chapter 5: PSYCHEDELIC DRUGS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Mental Health
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Abuse Disorder
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
Chapter 6: PSYCHEDELIC DRUGS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Mental Health Center
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
Chapter 7: PSYCHEDELIC DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Market size and forecast, by Drug Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Market size and forecast, by Drug Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Drug Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Market size and forecast, by Drug Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa
7.5.5.2.1. Market size and forecast, by Drug Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Rest of LAMEA
7.5.5.3.1. Market size and forecast, by Drug Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
Chapter 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
Chapter 9: COMPANY PROFILES
9.1. Numinus Wellness Inc
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Enveric Biosciences
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. Field Trip Health
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Johnson & Johnson (J&J)
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Havn Life
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. PharmaTher
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. Psyched Wellness
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Key strategic moves and developments
9.8. Apex Labs
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Ceruvia Lifesciences
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Braxia Scientific
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance



List of Figures

LIST OF FIGURES
FIGURE 01. PSYCHEDELIC DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PSYCHEDELIC DRUGS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN PSYCHEDELIC DRUGS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN PSYCHEDELIC DRUGS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL PSYCHEDELIC DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR KETAMINE, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR PSILOCYBIN, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR ABUSE DISORDER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. PSYCHEDELIC DRUGS MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH CENTER, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. PSYCHEDELIC DRUGS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 24. U.S. PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. JAPAN PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44. COMPETITIVE DASHBOARD
FIGURE 45. COMPETITIVE HEATMAP: PSYCHEDELIC DRUGS MARKET
FIGURE 46. TOP PLAYER POSITIONING, 2022
FIGURE 47. NUMINUS WELLNESS INC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 48. NUMINUS WELLNESS INC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 49. NUMINUS WELLNESS INC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. BRAXIA SCIENTIFIC: NET REVENUE, 2021-2022 ($MILLION)

List of Tables

LIST OF TABLES
TABLE 01. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. PSYCHEDELIC DRUGS MARKET FOR KETAMINE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PSYCHEDELIC DRUGS MARKET FOR PSILOCYBIN, BY REGION, 2022-2032 ($MILLION)
TABLE 04. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PSYCHEDELIC DRUGS MARKET FOR ABUSE DISORDER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 10. PSYCHEDELIC DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH CENTER, BY REGION, 2022-2032 ($MILLION)
TABLE 12. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. PSYCHEDELIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 21. CANADA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. CANADA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 24. MEXICO PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 27. EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. EUROPE PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 34. FRANCE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. UK PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. UK PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. ITALY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. ITALY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. SPAIN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. CHINA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. CHINA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. CHINA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. JAPAN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. JAPAN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. LAMEA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 69. BRAZIL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 70. BRAZIL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. BRAZIL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 73. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 75. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. NUMINUS WELLNESS INC: KEY EXECUTIVES
TABLE 79. NUMINUS WELLNESS INC: COMPANY SNAPSHOT
TABLE 80. NUMINUS WELLNESS INC: PRODUCT SEGMENTS
TABLE 81. NUMINUS WELLNESS INC: PRODUCT PORTFOLIO
TABLE 82. ENVERIC BIOSCIENCES: KEY EXECUTIVES
TABLE 83. ENVERIC BIOSCIENCES: COMPANY SNAPSHOT
TABLE 84. ENVERIC BIOSCIENCES: PRODUCT SEGMENTS
TABLE 85. ENVERIC BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 86. FIELD TRIP HEALTH: KEY EXECUTIVES
TABLE 87. FIELD TRIP HEALTH: COMPANY SNAPSHOT
TABLE 88. FIELD TRIP HEALTH: PRODUCT SEGMENTS
TABLE 89. FIELD TRIP HEALTH: PRODUCT PORTFOLIO
TABLE 90. JOHNSON & JOHNSON (J&J): KEY EXECUTIVES
TABLE 91. JOHNSON & JOHNSON (J&J): COMPANY SNAPSHOT
TABLE 92. JOHNSON & JOHNSON (J&J): PRODUCT SEGMENTS
TABLE 93. JOHNSON & JOHNSON (J&J): PRODUCT PORTFOLIO
TABLE 94. JOHNSON & JOHNSON (J&J): KEY STRATERGIES
TABLE 95. HAVN LIFE: KEY EXECUTIVES
TABLE 96. HAVN LIFE: COMPANY SNAPSHOT
TABLE 97. HAVN LIFE: PRODUCT SEGMENTS
TABLE 98. HAVN LIFE: PRODUCT PORTFOLIO
TABLE 99. HAVN LIFE: KEY STRATERGIES
TABLE 100. PHARMATHER: KEY EXECUTIVES
TABLE 101. PHARMATHER: COMPANY SNAPSHOT
TABLE 102. PHARMATHER: PRODUCT SEGMENTS
TABLE 103. PHARMATHER: PRODUCT PORTFOLIO
TABLE 104. PHARMATHER: KEY STRATERGIES
TABLE 105. PSYCHED WELLNESS: KEY EXECUTIVES
TABLE 106. PSYCHED WELLNESS: COMPANY SNAPSHOT
TABLE 107. PSYCHED WELLNESS: PRODUCT SEGMENTS
TABLE 108. PSYCHED WELLNESS: PRODUCT PORTFOLIO
TABLE 109. PSYCHED WELLNESS: KEY STRATERGIES
TABLE 110. APEX LABS: KEY EXECUTIVES
TABLE 111. APEX LABS: COMPANY SNAPSHOT
TABLE 112. APEX LABS: PRODUCT SEGMENTS
TABLE 113. APEX LABS: PRODUCT PORTFOLIO
TABLE 114. CERUVIA LIFESCIENCES: KEY EXECUTIVES
TABLE 115. CERUVIA LIFESCIENCES: COMPANY SNAPSHOT
TABLE 116. CERUVIA LIFESCIENCES: PRODUCT SEGMENTS
TABLE 117. CERUVIA LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 118. BRAXIA SCIENTIFIC: KEY EXECUTIVES
TABLE 119. BRAXIA SCIENTIFIC: COMPANY SNAPSHOT
TABLE 120. BRAXIA SCIENTIFIC: PRODUCT SEGMENTS
TABLE 121. BRAXIA SCIENTIFIC: PRODUCT PORTFOLIO